Unlocking The Potential of Ubiquitin-Conjugating Enzyme E2 as A Drug Target

Target Name: UBE2E2

NCBI ID: G7325

UBE2E2

Unlocking The Potential of Ubiquitin-Conjugating Enzyme E2 as A Drug Target

Ubiquitin-conjugating enzyme E2 (UBE2E2) is a protein that plays a crucial role in the regulation of protein degradation in the cell. It is a member of the ubiquitin enzyme family and is responsible for the covalent attachment of ubiquitin chains to target proteins. UBE2E2 is highly conserved across various species, and its sequence and structure have been well- conserved in the database.

UBE2E2 is a 22kDa protein that consists of 215 amino acid residues. It has a unique catalytic domain, which is composed of a parallel beta-sheet and a distinct 尾-hub. The 尾-sheet is responsible for the formation of the enzyme's active site , where the ubiquitin attachment occurs. The 尾-hub is a structural element that connects the different regions of the enzyme and plays a role in the stability and regulation of the enzyme.

UBE2E2 is regulated by various factors, including temperature, pH, and substrate concentration. The enzyme is highly stable at pH 7.0, and its stability increases as the pH increases. At pH 10.0, the stability of the enzyme decreases significantly due to the formation of aAmorphous aggregates. The substrate concentration also affects the stability of the enzyme, with low substrate concentrations leading to decreased stability.

The structure-based function analysis of UBE2E2 has provided insight into its mechanism of action. The enzyme has a unique substrate specificity, with different ubiquitin chains being attached to different target proteins. UBE2E2 can attach to the N-terminus of target proteins, which is known as the \"inward\" face of the protein. The orientation of the 尾-sheet and the 尾-hub allows the enzyme to efficiently attach to its substrate.

UBE2E2 has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. The high conservation of its sequence and structure across various species makes it an attractive target for drug development.

One of the advantages of UBE2E2 as a drug target is its high expression level in various tissues and cells. It is expressed in the cytoplasm, endoplasmic reticulum, peroxisomes, and mitochondria, which makes it an attractive target for small molecules and antibodies. Additionally, the protein is well-studied, which has provided a lot of insight into its structure-function relationships and the underlying mechanisms of its function.

Another advantage of UBE2E2 is its unique mechanism of action, which makes it different from other ubiquitin enzymes. Unlike other ubiquitin enzymes, which form a covalent complex with ubiquitin, UBE2E2 can directly form a covalent bond with ubiquitin through its 尾-sheet. This unique mechanism of action allows the enzyme to efficiently attach to its substrate and achieve its function with higher specificity and selectivity.

In conclusion, UBE2E2 is a unique and highly conserved protein that plays a crucial role in the regulation of protein degradation in the cell. Its high expression level, stability, and unique mechanism of action make it an attractive target for drug development and biomarker research. The study of its function and structure will provide valuable insights into the underlying mechanisms of its mechanism of action and its potential as a drug target and biomarker.

Protein Name: Ubiquitin Conjugating Enzyme E2 E2

Functions: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys-11'- and 'Lys-48'-, as well as 'Lys-63'-linked polyubiquitination. Catalyzes the ISGylation of influenza A virus NS1 protein

The "UBE2E2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2E2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets